title: Emergence of vancomycin-intermediate Staphylococcus aureus from predominant methicillin-resistant S. aureus clones in a Korean hospital.
abstract: The genetic and epidemiological features of four vancomycin-intermediate Staphylococcus aureus (VISA) isolates obtained from a Korean hospital were evaluated in this study. The VISA isolates were genotyped as sequence type (ST) 5-staphylococcal cassette chromosome mec (SCCmec) II variant (n=2) and ST239-SCCmec III (n=2), which were derived from the predominant methicillin-resistant S. aureus (MRSA) clones in Korean hospitals. One VISA isolate was acquired during vancomycin treatment, whereas three VISA isolates were obtained from the patients who had not previously been exposed to glycopeptides. As VISA is likely to arise from the predominant MRSA clones and may then possibly spread between patients, the emergence of VISA should be monitored with great care in hospitals.
authors.affiliation: Health and Environment Institute of Daegu, Daegu, Republic of Korea.
authors.forename: Hwa Yun
authors.initials: HY
authors.lastname: Cha
authors.forename: Hyun Ok
authors.initials: HO
authors.lastname: Kim
authors.forename: Jong Sook
authors.initials: JS
authors.lastname: Jin
authors.forename: Je Chul
authors.initials: JC
authors.lastname: Lee
mesh_terms: D017714:Community-Acquired Infections / Q000382:microbiology; D003428:Cross Infection / Q000382:microbiology*; D006761:Hospitals; D006801:Humans; D055624:Methicillin-Resistant Staphylococcus aureus / Q000187:drug effects / Q000235:genetics* / Q000302:isolation & purification; D056910:Republic of Korea; D013203:Staphylococcal Infections / Q000382:microbiology*; D013211:Staphylococcus aureus / Q000187:drug effects / Q000235:genetics* / Q000302:isolation & purification*; D020713:Vancomycin Resistance
references.citation: Microb Drug Resist. 2006 Spring;12(1):33-8
references.pmid: 16584306
references.citation: J Antimicrob Chemother. 1997 Jul;40(1):135-6
references.pmid: 9249217
references.citation: J Clin Microbiol. 2001 Jul;39(7):2439-44
references.pmid: 11427551
references.citation: J Clin Microbiol. 2000 Mar;38(3):1008-15
references.pmid: 10698988
references.citation: Curr Opin Pharmacol. 2003 Oct;3(5):474-9
references.pmid: 14559091
references.citation: J Clin Microbiol. 2005 Aug;43(8):3610-4
references.pmid: 16081886
references.citation: J Clin Microbiol. 2003 Jun;41(6):2279-81
references.pmid: 12791836
references.citation: Korean J Lab Med. 2008 Dec;28(6):444-8
references.pmid: 19127109
references.citation: Antimicrob Agents Chemother. 2002 Jul;46(7):2155-61
references.pmid: 12069968
references.citation: J Clin Microbiol. 2009 Nov;47(11):3617-23
references.pmid: 19759226
references.citation: J Microbiol. 2007 Oct;45(5):466-72
references.pmid: 17978808
references.citation: J Clin Microbiol. 2003 Apr;41(4):1574-85
references.pmid: 12682148
references.citation: J Clin Microbiol. 2001 Nov;39(11):4037-41
references.pmid: 11682527
references.citation: J Clin Microbiol. 1999 Nov;37(11):3556-63
references.pmid: 10523551
references.citation: J Clin Microbiol. 2000 Oct;38(10):3879-81
references.pmid: 11015427